Diagnosis and prognosis models for hepatocellular carcinoma patient’s management based on tumor mutation burden

Yang, 2019, A global view of hepatocellular carcinoma: trends, risk, prevention and management, Nat Rev Gastroenterol Hepatol, 16, 589, 10.1038/s41575-019-0186-y Forner, 2018, Hepatocellular carcinoma, Lancet (London, England), 391, 1301, 10.1016/S0140-6736(18)30010-2 Aravalli, 2008, Molecular mechanisms of hepatocellular carcinoma, Hepatology (Baltimore, MD), 48, 2047, 10.1002/hep.22580 Farazi, 2006, Hepatocellular carcinoma pathogenesis: from genes to environment, Nat Rev Cancer, 6, 674, 10.1038/nrc1934 Weston, 2004, Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine, J Proteome Res, 3, 179, 10.1021/pr0499693 Thorgeirsson, 2006, Functional genomics of hepatocellular carcinoma, Hepatology (Baltimore, MD), 43, S145, 10.1002/hep.21063 S.L. Topalian, J.D. Wolchok, T.A. Chan, I. Mellman, and K.D.J.C. Wittrup, Immunotherapy: The Path to Win the War on Cancer? 161 (2015) 185-6. Brown, 2018, Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research, Nat Rev Gastroenterol Hepatol, 15, 536, 10.1038/s41575-018-0033-6 Segal, 2008, Epitope landscape in breast and colorectal cancer, Cancer Res, 68, 889, 10.1158/0008-5472.CAN-07-3095 Alexandrov, 2013, Signatures of mutational processes in human cancer, Nature, 500, 415, 10.1038/nature12477 Snyder, 2014, Genetic basis for clinical response to CTLA-4 blockade in melanoma, New England J Med., 371, 2189, 10.1056/NEJMoa1406498 Melendez, 2018, Methods of measurement for tumor mutational burden in tumor tissue, Translat Lung Cancer Res, 7, 661, 10.21037/tlcr.2018.08.02 Chalmers, 2017, Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden, Genome Med, 9, 34, 10.1186/s13073-017-0424-2 Owada-Ozaki, 2018, Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non-Small Cell Lung Cancer: Brief Report, J Thoracic Oncol Off Publicat Int Assoc Study Lung Cancer, 13, 1217 Innocenti, 2019, Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome, J Clin Oncol Off J American Soc Clin Oncol, 37, 1217, 10.1200/JCO.18.01798 Boyd, 2013, Diagnostic applications of high-throughput DNA sequencing, Annual Rev Pathol, 8, 381, 10.1146/annurev-pathol-020712-164026 Liu, 2018, A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer, Transl Oncol, 11, 311, 10.1016/j.tranon.2018.01.011 Goodman, 2017, Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers, Mol Cancer Ther, 16, 2598, 10.1158/1535-7163.MCT-17-0386 Langfelder, 2008, WGCNA: an R package for weighted correlation network analysis, BMC Bioinf, 9, 559, 10.1186/1471-2105-9-559 Niemira, 2019, Molecular Signature of Subtypes of Non-Small-Cell Lung Cancer by Large-Scale Transcriptional Profiling: Identification of Key Modules and Genes by Weighted Gene Co-Expression Network Analysis (WGCNA), Cancers, 12, 10.3390/cancers12010037 Hänzelmann, 2013, GSVA: gene set variation analysis for microarray and RNA-seq data, BMC Bioinf, 14, 7, 10.1186/1471-2105-14-7 Tibshirani, 2011, Regression shrinkage selection via the LASSO, J Roy Stat Soc B, 73, 273, 10.1111/j.1467-9868.2011.00771.x Gentles, 2015, The prognostic landscape of genes and infiltrating immune cells across human cancers, Nat Med, 21, 938, 10.1038/nm.3909 Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, 12, 252, 10.1038/nrc3239 K.M. Olthoff, M.H. Rosove, C.R. Shackleton, D.K. Imagawa, D.G. Farmer, P. Northcross, A.L. Pakrasi, P. Martin, L.I. Goldstein, A. Shaked, and et al., Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma. Annals of surgery 221 (1995) 734-41; discussion 731-43. Cheng, 2020, PAWI-2 overcomes tumor stemness and drug resistance via cell cycle arrest in integrin β(3)-KRAS-dependent pancreatic cancer stem cells, Sci Rep, 10, 9162, 10.1038/s41598-020-65804-5 Higuchi, 2020, Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair, Clinical Cancer Res Off J American Assoc Cancer Res, 26, 1690, 10.1158/1078-0432.CCR-19-2000 Wojtuszkiewicz, 2015, Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance, Expert Opin Drug Metab Toxicol, 11, 673, 10.1517/17425255.2015.993316 Kojiro, 2004, Focus on dysplastic nodules and early hepatocellular carcinoma: an Eastern point of view, S3 Ogunwobi, 2019, Mechanisms of hepatocellular carcinoma progression, World J Gastroenterol, 25, 2279, 10.3748/wjg.v25.i19.2279 Fancello, 2019, Tumor mutational burden quantification from targeted gene panels: major advancements and challenges, J ImmunoTher Cancer, 7, 183, 10.1186/s40425-019-0647-4 Rizvi, 2015, Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science (New York, N.Y.), 348, 124, 10.1126/science.aaa1348 Balar, 2017, Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial, Lancet (London, England), 389, 67, 10.1016/S0140-6736(16)32455-2 Schmidt, 2017, Next-generation sequencing: big data meets high performance computing, Drug Discovery Today, 22, 712, 10.1016/j.drudis.2017.01.014 Nicholson, 2018, Dissecting the functions of SMG5, SMG7, and PNRC2 in nonsense-mediated mRNA decay of human cells, RNA (New York, N.Y.), 24, 557, 10.1261/rna.063719.117 Graack, 1992, YmL9, a nucleus-encoded mitochondrial ribosomal protein of yeast, is homologous to L3 ribosomal proteins from all natural kingdoms and photosynthetic organelles, Eur J Biochem, 206, 373, 10.1111/j.1432-1033.1992.tb16937.x Kudo, 2016, Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment, Liver cancer, 6, 16, 10.1159/000449343 Ikeda, 2015, Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future, Diseases (Basel, Switzerland), 3, 360 Ma, 2017, BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via MEK1/ERK/ELK1 signaling in hepatocellular carcinoma, Cancer Lett, 411, 117, 10.1016/j.canlet.2017.09.041 Riaz, 2016, The role of neoantigens in response to immune checkpoint blockade, Int Immunol, 28, 411, 10.1093/intimm/dxw019 Ladanyi, 2020, Immunologic and immunogenomic aspects of tumor progression, Semin Cancer Biol, 60, 249, 10.1016/j.semcancer.2019.08.011 Van Allen, 2015, Genomic correlates of response to CTLA-4 blockade in metastatic melanoma, Science (New York N.Y.), 350, 207, 10.1126/science.aad0095 Samstein, 2019, Tumor mutational load predicts survival after immunotherapy across multiple cancer types, Nat Genet, 51, 202, 10.1038/s41588-018-0312-8 Rehwinkel, 2005, Nonsense-mediated mRNA decay factors act in concert to regulate common mRNA targets, RNA (New York, N.Y.), 11, 1530, 10.1261/rna.2160905 Barreiros, 2012, Contrast enhanced ultrasound for the diagnosis of hepatocellular carcinoma (HCC): comments on AASLD guidelines, J Hepatol, 57, 930, 10.1016/j.jhep.2012.04.018 Parisi, 2012, Should a radiological diagnosis of hepatocellular carcinoma be routinely confirmed by a biopsy?, Yes. Eur J Intern Med, 23, 34, 10.1016/j.ejim.2011.10.015 Sakamoto, 1991, Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma, Hum Pathol, 22, 172, 10.1016/0046-8177(91)90039-R Terminology of nodular hepatocellular lesions. Hepatology (Baltimore, Md.) 22 (1995) 983-93.